Potrasertib: Difference between revisions

Browse history interactively Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 11:38, 29 December 2024 editBoghog (talk \| contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,879 edits created drug stubTag: nowiki added		Revision as of 01:05, 30 December 2024 edit undoJosve05a (talk \| contribs)Autopatrolled, Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers155,244 editsm clean up, added orphan tagTag: AWB Next edit →
Line 1:		Line 1:
			{{Orphan\|date=December 2024}}

	{{cs1 config\|name-list-style=vanc\|display-authors=6}}		{{cs1 config\|name-list-style=vanc\|display-authors=6}}
	{{Infobox drug		{{Infobox drug
Line 18:		Line 20:
	\| widthR =		\| widthR =
	\| altR =		\| altR =
	\| captionLR =		\| captionLR =

	<!-- Clinical data -->		<!-- Clinical data -->
Line 39:		Line 41:
	\| ATC_prefix =		\| ATC_prefix =
	\| ATC_suffix =		\| ATC_suffix =
	\| ATC_supplemental =		\| ATC_supplemental =

	<!-- Legal status -->		<!-- Legal status -->
Line 60:		Line 62:
	\| legal_UN =		\| legal_UN =
	\| legal_UN_comment =		\| legal_UN_comment =
	\| legal_status =		\| legal_status =

	<!-- Pharmacokinetic data -->		<!-- Pharmacokinetic data -->
Line 70:		Line 72:
	\| elimination_half-life =		\| elimination_half-life =
	\| duration_of_action=		\| duration_of_action=
	\| excretion =		\| excretion =

	<!-- Identifiers -->		<!-- Identifiers -->
Line 112:		Line 114:
	== References ==		== References ==
	{{reflist}}		{{reflist}}

⚫	{{pharma-stub}}

	]		]
Line 122:		Line 122:
	]		]
	]		]


		⚫	{{pharma-stub}}

Revision as of 01:05, 30 December 2024

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound

Potrasertib
Clinical data

Other names	IMP7068
Identifiers
IUPAC name 7-(2,6-dichlorophenyl)-12-anilino]-2,5,7,11,13-pentazatricyclotrideca-1(13),5,9,11-tetraen-8-one
CAS Number	2226938-19-6
PubChem CID	139503236
UNII	621K13UG4B
Chemical and physical data
Formula	C₂₈H₃₀Cl₂N₈O
Molar mass	565.50 g·mol
3D model (JSmol)	Interactive image
SMILES C1CN(C(N1C)C)C2=C(C=C(C=C2)NC3=NC=C4C(=N3)N5CCN=C5N(C4=O)C6=C(C=CC=C6Cl)Cl)C
InChI InChI=InChI=1S/C28H30Cl2N8O/c1-16-12-19(8-9-23(16)36-14-17(2)35(4)18(3)15-36)33-27-32-13-20-25(34-27)37-11-10-31-28(37)38(26(20)39)24-21(29)6-5-7-22(24)30/h5-9,12-13,17-18H,10-11,14-15H2,1-4H3,(H,32,33,34)/t17-,18+ Key:BNVDJVMTLDUCGH-HDICACEKSA-N

Potrasertib is an investigational new drug that is being evaluated for the treatment of advanced solid tumors. It is oral inhibitor of WEE1 kinase, a key regulator of cell cycle checkpoints, currently being developed by IMPACT Therapeutics.

References

"IMP 7068". AdisInsight. Springer Nature Switzerland AG.
Wang Z, Li W, Li F, Xiao R (January 2024). "An update of predictive biomarkers related to WEE1 inhibition in cancer therapy". Journal of Cancer Research and Clinical Oncology. 150 (1): 13. doi:10.1007/s00432-023-05527-y. PMC 10794259. PMID 38231277.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: